Literature DB >> 1772296

Effect of misoprostol on concentrations of prostaglandins in synovial fluid.

A Doube1, J Davies, L Notarianni, K Holgate, G C Fenn.   

Abstract

The effect of misoprostol, a synthetic analogue of prostaglandin E, on prostaglandin concentrations in synovial fluids was investigated in a randomised placebo controlled, double blind study. The synovial fluid concentrations of prostaglandin E1, 6-keto-prostaglandin F1 alpha, and thromboxane B2 were measured at the beginning and end of a 24 hour period in 25 patients with effusions of the knee joint. During this period the patients were treated with diclofenac (50 mg every eight hours) and either misoprostol (400 micrograms) or placebo every 12 hours. The concentrations of prostaglandin E and 6-keto-prostaglandin F1 alpha were not significantly altered during treatment. There was an unexpected significant reduction in thromboxane B2 concentrations in the group treated with misoprostol (within group analysis). Although the mean concentration with misoprostol was about half the mean concentration with placebo, this difference was not statistically significant in the between group analysis. These results indicate that misoprostol is unlikely to exert a proinflammatory effect or to interfere with the prostaglandin mediated effects of non-steroidal anti-inflammatory drugs. The significant decrease in thromboxane B2 concentrations in the misoprostol treated group suggests that misoprostol may exert an anti-inflammatory effect.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1772296      PMCID: PMC1004561          DOI: 10.1136/ard.50.11.797

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

1.  Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone.

Authors:  M Moran; M F Mozes; M S Maddux; S Veremis; C Bartkus; B Ketel; R Pollak; C Wallemark; O Jonasson
Journal:  N Engl J Med       Date:  1990-04-26       Impact factor: 91.245

2.  A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract, in patients with osteoarthritis.

Authors:  A J Collins; J Davies; A S Dixon
Journal:  Br J Rheumatol       Date:  1988-04

3.  Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial.

Authors:  D Y Graham; N M Agrawal; S H Roth
Journal:  Lancet       Date:  1988-12-03       Impact factor: 79.321

4.  Stimulation of duodenal bicarbonate secretion by misoprostol.

Authors:  B Smedfors; C Johansson
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

5.  Non-steroidal anti-inflammatory drugs and pain free peptic ulceration in the elderly.

Authors:  M P Skander; F P Ryan
Journal:  BMJ       Date:  1988-10-01

6.  Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer.

Authors:  K Somerville; G Faulkner; M Langman
Journal:  Lancet       Date:  1986-03-01       Impact factor: 79.321

7.  Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration.

Authors:  C P Armstrong; A L Blower
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

8.  Prostaglandin E2 inhibits the activation of cloned T cell hybridomas.

Authors:  G T Makoul; D R Robinson; A K Bhalla; L H Glimcher
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

9.  A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration.

Authors:  F Lanza; K Peace; L Gustitus; M F Rack; B Dickson
Journal:  Am J Gastroenterol       Date:  1988-02       Impact factor: 10.864

10.  Peptic ulcer in rheumatoid arthritis.

Authors:  D Farah; R D Sturrock; R I Russell
Journal:  Ann Rheum Dis       Date:  1988-06       Impact factor: 19.103

View more
  4 in total

Review 1.  Misoprostol/NSAID fixed combinations. Help or hindrance in clinical practice?

Authors:  A Isdale; V Wright
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

2.  The Protective Effects of VVN001 on LPS-Induced Inflammatory Responses in Human RPE Cells and in a Mouse Model of EIU.

Authors:  Ruiqi Qiu; Mingzhu Yang; Weiping Wang; Jingyang Liu; Lin Yang; Bo Lei
Journal:  Inflammation       Date:  2020-11-16       Impact factor: 4.092

3.  Misoprostol inhibits gastric mucosal release of endogenous prostaglandin E2 and thromboxane B2 in healthy volunteers.

Authors:  A Mertz-Nielsen; O Eskerod; K Bukhave; J Rask-Madsen
Journal:  Gut       Date:  1995-04       Impact factor: 23.059

Review 4.  Misoprostol in the prevention of gastroduodenal damage in rheumatology.

Authors:  A B Ballinger; P J Kumar; D L Scott
Journal:  Ann Rheum Dis       Date:  1992-09       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.